Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02560012 · ClinicalTrials.gov registry record · Phase 2
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02560012 is a Phase 2 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 4 participants.
The verdict
NCT02560012, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is for subjects with metastatic Renal Cell Cancer (RCC). There are four Food and Drug Administration (FDA) approved drugs for first-line therapy of Renal Cell Cancer (RCC) and two for second-line therapy. Each of these drugs targets a specific molecular pathway. At present oncologists select therapy based on current guidelines. There is a new method for trying to use biomarker information from the subject's tumor to select the best drug to treat the subject. This process is investigational, which is why this study is being done. Biomarkers are genes, proteins and other molecules that affect how cancer cells grow, multiply, die and respond to other compounds in the body. These biomarkers build a tumor profile or "fingerprint" of the subject's tumor. A new focus in cancer care is personalized treatment, where doctors select a drug based on the subject's tumor's unique "fingerprint" which is more likely to be effective in fighting the tumor. Selecting the treatment the subject is more likely to respond to requires a thorough understanding of the relationship between biomarker and treatment effect. The PI wants to gather data to understand that relationship to help treat future cancer patients. The purpose of this study is to evaluate efficacy of treatments that are selected based on tumor profiles.
Interventions
- DRUG Everolimus
- DRUG Sunitinib
- DRUG Sorafenib
- DRUG Temsirolimus
- DRUG Pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-01-04 |
| Est. Completion | 2017-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02560012
The ClinicalTrials.gov registry entry for NCT02560012 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Everolimus is the first listed.
NCT02560012 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02560012 about?
NCT02560012 is a clinical study titled "Personalized Targeted Inhibitors Treatment in Renal Cell Cancer". This is for subjects with metastatic Renal Cell Cancer (RCC). There are four Food and Drug Administration (FDA) approved drugs for first-line therapy of Renal Cell Cancer (RCC) and two for second-line therapy. Each of these drugs targets a specific molecular pathway. At present oncologists select th...
What is the current status of trial NCT02560012?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2016-01-04. Estimated completion is 2017-07-27.
What interventions are being tested in trial NCT02560012?
The interventions under investigation include: Everolimus (DRUG), Sunitinib (DRUG), Sorafenib (DRUG), Temsirolimus (DRUG), Pazopanib (DRUG).
Who is sponsoring clinical trial NCT02560012?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.